Original Research

Synergic radiosensitization of sinomenine hydrochloride and radioiodine on human papillary thyroid carcinoma cells

Aomei Zhao a, Jing Zhang a, Yan Liu a, Xi Jia a, Xueni Lu a, Qi Wang a, Ting Ji a, Lulu Yang a, Jianjun Xue a, Rui Gao a, Yan Yu b, Aimin Yang a,∗

a Department of Nuclear Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, PR China
b Department of Public Health, Health Science Center of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, PR China

ARTICLE INFO

Keywords:
Sinomenine hydrochloride
Iodine-131
Papillary thyroid carcinoma cell
Radio sensitivity
Apoptosis

ABSTRACT

Radioiodine (131I) therapy is an important treatment for thyroid carcinoma. The response to radiotherapy sometimes limited by the development of radioresistance. Sinomenine hydrochloride (SH), was reported as a prospective radiosensitizer. This study was aim to evaluate synergic radiosensitization of SH and 131I on papillary thyroid carcinoma (PTC). We evaluated HTori-3, BCPAP and TPC-1 cells, the cell viability was evaluated by MTT. The experiment was divided into 4 groups: control group, SH (0.8 mM) group, I (131I 14.8 MBq/ml) group and ISH (SH 0.8 mM plus 131I 14.8 MBq/ml) group. Flow cytometry was used to investigate cell cycle phases and cell apoptosis. RT-PCR and western blotting were performed to determine the molecular changes. Compared to control group, SH significantly increased apoptosis and enhanced radiosensitivity of HTori-3 and PTC cells were related to the ratio of Bcl-2 to Bax protein downregulation and Fas, p21, p-ATM, p-Chk1, p-Chk2 and p53 protein expression upregulation in the ISH group (P < 0.05). Our results indicate that synergic radiosensitization of SH and iodine-131 on PTC cells and SH could be a potential therapeutic radiosensitizer in PTC radio therapy after total thyroidectomy.

Introduction

In recent years, the incidence of thyroid cancer has increased rapidly worldwide. Papillary thyroid cancer (PTC) constitutes approximately 80% of all thyroid cancer cases [1–3]. RAI is one of the most important therapy of PTC. Although most PTC cases have a quite favorable prognosis after standard therapeutic approaches, including surgery, selective radioactive iodine (RAI) therapy, and thyroid stimulating hormone (TSH) suppressive therapy, there are still some patients who are gradually insensitive to iodine and have a poor therapeutic effect [4]. Patients may fail it when the cancer has lost radiiodine avidity; a primary cause for PTC related morbidity and mortality. There are many studies on the mechanism of radiation resistance of PTC cells at present, but it will take a long time to convert into clinical radiosensitizer [5–8]. Therefore, it is urgent to find a radiosensitizer, which can be used in clinic as soon as possible.

The alkaloid sinomenine is extracted from the Chinese medical plant Sinomenium acutum. Within the past 30 years, the therapeutic efficacy and lower side effects of sinomenine in patients with rheumatoid arthritis (RA) have been confirmed in open clinical trials [9,10]. Moreover, Sinomenine hydrochloride (SH) has already been effectively used in rheumatoid arthritis during clinical practice [11]. Recently, several studies have demonstrated that SH not only has antineoplastic effects against various types of cancer, including lung cancer, gastric adenocarcinoma, breast cancer, but also it has been found that SH appears to be a prospective radiosensitizer in cervical cancer and esophageal squamous cell carcinoma therapy [12–16]. Zhang et al. found that SH sensitized human cervical cancer cell line cells to ionizing radiation (IR) by promoting accumulation of IR-induced DNA double-strand breaks (DSBs) and by interfering with the DNA damage checkpoint activation [15]. Fu et al. found that SH could improve the sensitivity of radiation in esophageal squamous cell carcinoma cells by inducing G2/M phase arrest, promoting radiation-induced apoptosis and inhibiting DSB-repair pathways [16]. However, its effect on thyroid cancer is unclear till now.

The radioresistance of thyroid cells were related with different
molecular. Depending on molecular investigations, it is believed that mutations in RAS (rat sarcoma), BRAF (B-Raf proto-oncogene) and RET (rearranged during transfection)/PTC rearrangement, which take part in mitogen activated protein kinases (MAPK) pathway, cause an aberrant activation and lead to the development of PTC [17]. Several studies reveal that the most widespread molecular damage in thyroid cancer is caused by BRAF mutation (29–83%) [18]. With this in mind, in the present study we determined the synergic radiosensitization of sinomene hydrochloride and radioiodine of both in the papillary thyroid cells and normal thyroid cells and whether the different radioresistance caused by a BRAF mutation or not. Meanwhile, we aimed to clarify the molecular mechanisms underpinning these effects in the human thyroid cancer cell line. Thus, in this study, we used V600E mutation (BRAFV600E: 8505C, BCPAP, SW-1736) or the cells of BRAF WT (BRAFWT: U-Hth-74, TPC-1) thyroid cancer cell lines, thereby representing the most common genetic alterations found in PTC, meanwhile the HTori-3 was taken as normal thyroid cells for contrast.

Materials and methods

Cell cultures and preparation of SH

The HTori-3, BCPAP and TPC-1 cell line were provided by Professor Peng Hou (Endocrinology Laboratory, The First Affiliated Hospital of Xi’an Jiaotong University of Medicine, Xi’an, China). The HTori-3 and TPC-1 cells were cultured in DEME/F12 medium (Hyclone, Logan, UT, USA) and supplemented with 10% Certified FBS (04–001–1ACS, Biological Industries, Israel) and 1% penicillin/streptomycin (Hyclone) in a 5% CO₂ humidified atmosphere at 37°C. The BCPAP cells were cultured in RPMI 1640 medium (Hyclone, Logan, UT, USA), 1% sodium pyruvate (Gibco, No.11360070), 1% nonessential amino acids (Gibco, No.11140050) and supplemented with 10% certified FBS (04–001–1ACS, Biological Industries, Israel) and 1% penicillin/streptomycin (Hyclone) in a 5% CO₂ humidified atmosphere at 37°C.

SH (B21440 Shanghai Yuanye Biotechnology Co., Ltd. China) was dissolved in phosphate-buffered saline (PBS) to a concentration of 100 mM, and stored at -20°C for up to 4 weeks.

Methylthiazoltetrazolium (MTT) assay

The cells were seeded at 1.5 × 10⁴/ml in 96-well plates for 24 h, 48 h, 72 h. SH solutions were prepared with the same culture medium as HTori-3, BCPAP and TPC-1 cells with final gradient concentrations of 0.2, 0.4, 0.8, 1 and 2 mM, while identical volumes of PBS were added to the control wells. After the cells were incubated for 24, 48 and 72 h, 20µl 3- (4, 5-dimethylthiazol-2-yi) -2, 5-diphenyterrazolium bromide was added to each well and the cell cultures were incubated for an additional 4 h. The medium was discarded and the formazan crystals were solubilized in 150µl/well DMSO. The colored solution was quantified by a spectrophotometer at an absorbance of 490 nm. The inhibition rate of the cells was then calculated. The absorbance was directly associated with the viable cell number. The experiment was performed at least in triplicate.

The cells were seeded at 1.5 × 10⁴/ml in 96-well plates for 12 h, 24 h, and 48 h. Radio-I solutions were prepared with the same culture medium as HTori-3, BCPAP and TPC-1 cells with final gradient concentrations of 7.4, 14.8 and 29.6 MBq/ml, while identical volumes of PBS were added to the control wells. After the cells were incubated for 12, 24 and 48 h, 20µl 3- (4, 5-dimethylthiazol-2-yi) -2, 5-diphenyterrazolium bromide was added to each well and the cell cultures were incubated for an additional 4 h. The medium was discarded and the formazan crystals were solubilized in 150 µl/well DMSO. The colored solution was quantified by a spectrophotometer at an absorbance of 490 nm. The inhibition rate of the cells was then calculated. The absorbance was directly associated with the viable cell number. The experiment was performed at least in triplicate.

Cell apoptosis and cell cycle assay

A cell apoptosis assay was performed using an Annexin V-FITC/PI Apoptosis Detection Kit (Shanghai Qihai Futai Biotechnology Co., Ltd., China). The HTori-3, BCPAP and TPC-1 cells were seeded at 5 × 10⁴/ml in 6-well plates for 24 h and then divided into 4 groups: control group, SH (0.8 mM) group, I-131 (iodine-131 14.8 MBq/ml) group, ISH (SH 0.8 mM plus iodine-131 14.8 MBq/ml) group. The follow Cells were treated with SH for 24 h, and then treated with iodine-131. The density plots show cell populations (live, early apoptosis, necrosis, and late apoptosis or dead cells) according to their fluorescence characteristics.

Cell cycle of apoptosis was quantitated using the Cell Cycle and Apoptosis Analysis Kit (C1052, Shanghai Biyunian Biotechnology Co., Ltd., China) following the manufacturer’s instructions. Cells were fixed with 70% ethanol (2 h, 4°C), and stained with propidium iodide and RNase A (30 min, 37°C) for cell cycle analysis.

Western blotting

The cells were lysed with RIPA lysis buffer (Shanghai Biyunian Biotechnology Co., Ltd., China) and the protein concentrations were quantified using a BCA kit (Shanghai Biyunian Biotechnology Co., Ltd., China). Total protein (~150 µg) was denatured in loading buffer at 100°C for 8 min and electrophoresed using 10% sodium dodecyl sulfatae-polyacrylamide gel electrophoresis (SDS-PAGE). Lysters containing 150 µg proteins were subjected to SDS-PAGE, followed by transfer of proteins to a polyvinylidene difluoride membrane (EMD Millipore, Billerica, MA, USA). The membranes were blocked with 5% non-fat milk in Tris–buffered saline with 0.05% Tween-20 at pH 7.5 for 1 h. And then, the membranes were incubated at 4°C with the following primary antibodies: The Bcl-2 antibody (Abcam ab196495 1:2000), Bax antibody (Abcam ab32503 1:2000), p53 antibody (Abcam ab241566 1:1000), phosphor-ATM S1981 antibody (Abcam ab81292 1:10,000), p21 antibody (Proteintech Group Inc. China,10,335–1-AP, 1:1000), GADPH antibody (Proteintech Group Inc. China, 60,004–1-lg 1:10,000), phosphor-Chk2 Thr68 antibody (Cell Signaling Technology. no. 2661 1:1000), phosphor-Chk1 Ser345 antibody (Cell Signaling Technology no. 2348 1:1000) and Fas antibody (Cell Signaling Technology no. 4233 1:1000) and then incubated with secondary anti-rabbit or -mouse immunoglobulin (Proteintech Group Inc. China) for 1 h at 37°C. The membranes were washed 3 times with Tris-buffered saline with 0.05% Tween-20 and once with Tris-buffered saline.

RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

The RNA was extracted from cells with TRIzol reagent (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer’s instructions. The concentration of total RNA was determined using a spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA) and the 260/280 absorbance ratio, used to investigate the sample purity, was between 1.8 and 2.0. The cDNA synthesis was performed using 500 ng total RNA in a reaction volume of 10µl. The thermal cycling conditions were as follows: 15 min at 37°C and 5 s at 85°C. The copy number quantification was performed with RT-qPCR using GADPH as the internal reference. The primer sequences of Bcl-2, Bax, p53, p21, ATM, Fas and GADPH are shown in Table 1. Following reverse transcription, the conditions were as follows: 95°C for 30 s, 40 cycles of 5 s at 95°C and 30 s at 60°C for annealing and extensions were run on a Roche LightCycler96 Real-time Fluorescence Quantitative PCR Instrument (Roche Diagnostics GmbH Sandhofer Straße 116 68,305 Mannheim, Germany). The results were analyzed using the SYBR® Premix Ex Taq™ II (No. RR820A) Master Mix(RR036A) and the SYBR® Premix Ex Taq™ II (No. RR820A) was purchased from Takara Biotechnology Co., Ltd. (Dalian, China) and used for real-time PCR. All real-time PCR experiments were performed in triplicate.
Statistical analysis

Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). Differences between the control and treatment groups were determined by Student’s t-test and considered to be significant at $P < 0.05$.

Results

**SH inhibited thyroid cell proliferation**

To address this question, first, we tested the effect of SH on HTori-3, BCPAP and TPC-1 cells by performing MTT-based cell viability analysis (Fig. 1). The cell viability inhibition rate was calculated at 24, 48 and 72 hours after treatment.
h after SH treatment and as shown in Fig. 1A, B and C, cellular survival was significantly inhibited by SH at various concentrations. When at 24 h, concentrations of 1.0 and 2 mM induced severe cell death (40 to 60%), while 0.2, 0.4 and 0.8 mM SH exhibited a similar and relatively moderate effect on cell survival compared with higher concentrations (Fig. 1A, B and C). A higher 35.89% inhibition of cell growth was observed at a concentration of 0.8 mM in TPC-1 cells after 24 h compared with 21.76% inhibition that observed in BCPAP cells, and 16.82% inhibition, which observed in HTori-3 cells (Fig. 1D).

Given that 1 mM was an already established concentration in previously published studies for a number of carcinoma cell lines [11, 12], thus safe concentration of SH (0.8 mM) was selected for the subsequent experiments.

**Iodine-131 inhibits cell growth in a time- and dose-dependent manner**

In order to investigate the effect of iodine-131 on HTori-3, BCPAP and TPC-1 cells, thyroid cells were incubated with various concentrations of iodine-131 (7.4, 14.8 or 29.6 MBq/ml) for designated time periods (12, 24 and 48 h) and the cell viability was determined using an MTT assay. The results (Fig. 2) revealed that iodine-131 produced a significant inhibition of cell growth compared with the control group. A higher 20.3% inhibition of cell growth was observed at a dose of 14.8MBq/ml in TPC-1 cells after 24 h compared with 13.9% inhibition, which observed in BCPAP cells, and 12.8% inhibition which observed in HTori-3 cells (Fig. 2D). And a select dose of iodine-131 (14.8 MBq/ml) treated for 24 h was selected for the following experiments.

**SH could enhance the rate of apoptosis in thyroid cells treated with iodine-131**

Annexin V-FITC and PI dual staining were used to measure whether iodine-131 and SH could induce apoptosis in HTori-3, BCPAP and TPC-1 cells. We next conducted flow cytometric analysis to test apoptosis in HTori-3, BCPAP and TPC-1 cells incubated with four groups, and observed significantly increased apoptosis in group ISH compared with the other groups (Fig. 3A, B and C).

In comparison with the control group, SH group exhibited a slight increase in apoptosis level while I-131 group and ISH group both induced a moderate level of apoptosis, moreover, there was a significant difference found between I-131 group and ISH group in HTori-3 cells, BCPAP cells and TPC-1 cells ($P < 0.05$) (Fig. 3D, E and F). (Table II)

---

![Fig. 2.](image-url) Iodine-131 inhibits the viability of HTori-3, BCPAP and TPC-1 cells in vitro. (A) HTori-3, (B) BCPAP and (C)TPC-1 cells were incubated with iodine-131 at the indicated concentrations for various time-points. An MTT assay was performed 24 h after treatment. (D) The cell viability of cell growth among three cells in the condition of iodine-131(14.8MBq/ml) treated after 24 h ($^*P < 0.05$). The data are presented as the mean ± standard deviation of three independent experiments.
When contrasting apoptosis of ISH group among three cell lines, a higher 58.39% apoptosis in TPC-1 cells and a higher 54.88% apoptosis in BCPAP cells were observed when compared with a 38.51% apoptosis rate of HTori-3 cells (*P < 0.05). (Fig. 3 H).

The effect of SH plus iodine-131 on cell cycles in HTori-3, BCPAP and TPC-1 cells

To identify whether SH can affect iodine-131 induced cell cycle distribution, PI staining in HTori-3, BCPAP and TPC-1 cells were evaluated (Fig. 4A, B and C).

Cell cycle analysis demonstrated that SH combined with iodine-131 arrested HTori-3, BCPAP and TPC-1 cells in the G2/M phase. Among three kinds of cells, the number of cells in G2/M phase was lower in the ISH group than it in the I-131 group (P < 0.05), meanwhile the number of cells in S phase was significantly higher in the ISH group than it in I-131 group in HTori-3, BCPAP and TPC-1 cells (P < 0.05) (Fig. 4D, E and F).

When contrasting the cells in the G2/M phase of group ISH among three cell lines, the number in G2/M phase of HTori-3, BCPAP and TPC-1 cell lines were increasing difference in proper order showed in Fig. 4H (P < 0.05). Notably the sensitive effect of SH in TPC-1 cells is more pronounced than the other cell lines (*P < 0.05).

**Table II**
The rate of apoptosis in thyroid cells treated with SH and iodine-131.

|        | Control | SH    | I    | ISH   |
|--------|---------|-------|------|-------|
| HTori-3| 13.93% ± 0.92% | 24.89% ± 1.09% | 35.47% ± 0.47% | 38.51% ± 0.83% |
| BCPAP  | 7.69% ± 4.11% | 42.78% ± 0.89% | 44.92% ± 3.7% | 56.98% ± 5.41% |
| TPC-1  | 7.11% ± 1.09% | 13.01% ± 0.01% | 40.07% ± 8.86% | 56.01% ± 7.34% |

SH, sinomenine hydrochloride; I, iodine-131; ISH, co-treatment of iodine-131 and SH.

SH regulated the protein expression of Bcl-2, Bax, p21, p53, and Fas in HTori-3, BCPAP and TPC-1 cells

To understand the molecular mechanisms underlying the SH and iodine-131 induction of apoptosis and regulation of cell cycle, the protein expression of Bcl-2, Bax, p53 and p21 were examined by western blot analysis in HTori-3, BCPAP and TPC-1 cells (Fig. 5A).

In HTori-3 cells, the level of Bax and Fas, were highly upregulated in ISH group when compared with control group, while the expression of Bcl-2 was down-regulated. In BCPAP cells, the level of Bax, p21, p53 and Fas, were highly upregulated in ISH group when compared with control groups, while the expression of Bcl-2 was almost no change. In TPC-1 cells, the level of p21, p53 and Fas, were highly upregulated in the ISH group when compared with control group, while the expression of Bcl-2 was down-regulated, meanwhile the level of Bax was almost no change.

Furthermore, we evaluated the expression levels of Bcl-2, p21, p53, Bax and Fas were determined using RT-qPCR in HTori-3, BCPAP and TPC-1 cells, and we evaluated the ratio of Bcl-2 to Bax. The mRNA expression of Fas, p53 and p21 were found to be transcriptionally increased in ISH group when compared with I-131 group (P < 0.05) (Fig. 5C, D and E), while the ratio of Bcl-2 to Bax mRNA expression decreased following added SH treatment (P < 0.05) (Fig. 5B), which were observed in all HTori-3, BCPAP and TPC-1 cells.

When analyzing these genes specifically in ISH group, we figured out that Fas and p53 mRNA expression were transcriptionally increased in the order of HTori-3, BCPAP and TPC-1 cells determined by RT-qPCR.
with SH and/or exposed to iodine-131 (14.8 MBq/ml), and then analyzed using flow cytometry. The distribution of cell cycle phases is revealed in the histogram in D, and p-Chk2 were highly upregulated in ISH group when compared with I-131 group, meanwhile the ATM mRNA expression transcriptionally determined by RT-qPCR (Fig. 6). From our result show in Fig. 5 and Fig. 6, we found that followed by treated with SH and iodine-131, the radiation induced an up-regulation of p-ATM, p-Chk1 and p-Chk2 in the same time. In addition, an up-regulation of p53 and p21 caused by uprend of ATM also made effort on cell cycle in PTC cells.

Discussion

Radioactive iodine-131 is a cornerstone in the routine adjuvant management in patients with high-risk differentiated thyroid cancer (DTC), although it is sometimes limited by the development of radioresistance [4]. Thus, it is of great importance to identify a way to promote the radiosensitivity of PTC and improve tumor control. Several studies provide evidence that SH is a promising radiosensitizer both in cervical cancer and in esophageal squamous cell for improving the therapeutic efficacy of radiation [19,20]. In the present study, we investigated the increase effects of SH combined with iodine-131 treatment on thyroid cells (HTori-3, BCPAP and TPC-1 cells) in vitro. The results of present study revealed that synergic radiosensitization of SH and iodine-131 of SH and iodine-131 on HTori-3, BCPAP and TPC-1 cells was related to apoptosis and DNA damage repair.

Apoptosis plays a vital role in all kinds of diseases, and it is considered the primary process of cell death following radiotherapy [21]. It is activated intrinsic (mitochondrial death pathway which is dominated by the Bcl-2 family of proteins) and extrinsic pathways (death receptor pathway which is dominated by the cell surface receptor, Fas (CD95/Apo-1)). The Bcl-2 family that is divided into proapoptotic proteins, including Bax, and anti-apoptotic proteins, including Bcl-2, regulates the former pathway [22]. There is increasing evidence that the whether cell undergo apoptosis depends on the ratio of anti-and pro-apoptotic members, especially the ratio of Bcl-2 to Bax [23,24]. During extrinsic pathways, Fas is known to be critical in the process of cell apoptosis induced by radiation damage and other DNA damage [25, 26]. p21 appears could protect from cell death through various mechanisms, including growth arrest and cytoplasmic effect [27]. p21 could activate by p53, In p53-dependent apoptotic signaling pathway, p21 is indirectly involved in apoptosis through cell cycle arrest, which means it is still unclear whether a physiologic complex of p53/p21/Bcl-2 regulates apoptosis [28]. SH has been demonstrated to sensitize radiation in various cancer cells. As for ESCC cells, SH enhanced radiosensitivity was related to Bcl-2 down-regulation and Bax protein expression up-regulation [16]. Our results demonstrated that iodine-131 and SH could synergistically increase the fraction of apoptotic cells. To investigate the mechanisms underpinning this synergistic effect, we performed Western blot and RT-qPCR analysis. In this present study, co-treatment of PTC cells and normal thyroid cells resulted in decreasing the ratio of Bcl-2 to Bax and significantly increased Fas expression levels, indicating that the Bcl-2, Bax and Fas expression levels are involved in signal transmission in the process of cell apoptosis induced by iodine-131 radiation and promoted by SH efforts. In addition, the apoptosis induced by iodine-131 may occur through the death receptor pathway and the mitochondrial pathway and enhanced by SH in PTC cells and normal thyroid cells. Interestingly, we found that SH played a more significant role in PTC cells compared with normal thyroid cells under the same conditions. Therefore, we can imagine that SH may also be used in Graves’ disease iodine-131 treatment, which needs

**Fig. 4.** Cell cycle changes induced by SH and I-131 in HTori-3, BCPAP and TPC-1 cells. (A and D) HTori-3, (B and E) BCPAP and (C and F) TPC-1 cells were pretreated with SH and/or exposed to iodine-131 (14.8 MBq/ml), and then analyzed using flow cytometry. The distribution of cell cycle phases is revealed in the histogram in D, and F (*P < 0.05). The data are presented as the mean ± standard deviation of three independent experiments. (H) Compare the distribution of cell cycle phases of ISH group among three cell lines (*P < 0.05). SH, sinomenine hydrochloride; I, iodine-131; ISH, co-treatment of iodine-131 and SH; PI, propidium iodide.

**SH enhances expression of p-ATM and the iodine-131-induced activation of Chk1 and Chk2**

In HTori-3, BCPAP and TPC-1 cells, the level of p-ATM, p-Chk1 and p-Chk2 were highly upregulated in ISH group when compared with I-131 group, meanwhile the ATM mRNA expression transcriptionally increased determined by RT-qPCR. (Fig. 6). When analysis the ATM mRNA expression of ISH group, it was lowest in BCPAP than the other two cell lines (HTori-3 and TPC-1 cells) determined by RT-qPCR (*P < 0.05) (Fig. 6D). From our result show in Fig. 5 and Fig. 6, we found that followed by treated with SH and iodine-131, the radiation induced an up regulation of p-ATM, p-Chk1 and p-Chk2 in the same time. In addition, an up regulation of p53 and p21 caused by uprend of ATM also made effort on cell cycle in PTC cells.
Following irradiation, the DNA damage checkpoint responses and DNA repair machinery are important in cellular response to radiation [29]. To maintain genome stability, organisms have evolved a complex network of DNA damage response (DDR) mechanisms, including DNA repair, DNA damage checkpoint mechanisms and programmed cell death. Double-strand break sensor (DSB) induces activation of the DNA damage checkpoint, resulting in cell cycle arrest to allow enough time for DSB repair and prevent mitosis in the presence of a broken chromosome [30]. DDR is a kinase-based signal transduction pathway that involves multiple DSB sensor proteins such as DNA repair proteins, transducer proteins such as ATM and ATR, mediator proteins such as 53BP1 and BRCA1, and effectors such as Chk1 and Chk2, which protect and maintain genome stability [31,32]. ATM is a serine/threonine kinase that regulates cell cycle checkpoints and DNA repair [33]. Activation of ATM by auto phosphorylation on Ser1981 occurs in response to expose DNA double stranded breaks. ATM kinase regulates a number of proteins involved in cell cycle checkpoint control, apoptosis, and DNA repair [34]. As many studies reported, upon cell DNA damage caused by radiation, ATR and ATM phosphorylate Chk1 and Chk2 at Serine 345 (S345) and Threonine 68 (T68), respectively, facilitating G1/S, intra-S and G2/M cell cycle checkpoint activation [35–38]. SH could cause DNA damage accumulation and interfered with cell-cycle checkpoint activation in Hela cells and ESCC cells [15,16]. Similarly, in our study, we demonstrated that the co-treatment of SH and iodine-131 could inhibit DSB-repair pathways and cause a rise of ATM, p-Chk1 and p-Chk2 protein expression in both PTC cells and normal thyroid cells. During DDR after radiation, there are still many other DSB sensor proteins, which may require further study.

The sensitivity of cells to radiation is related to the cell cycle phase. It has been reported that cells in the specific cell cycle phases exhibit different degrees of radiosensitivity. In general, cells are most sensitive to irradiation in the G2 and M phases [39–41]. Many studies have demonstrated that many radiosensitizing agents, such as SH for cervical cancer and esophageal squamous cell carcinoma and valproic acid for thyroid cancer cells increase the cells in the G2/M cell cycle, which enhances the radiosensitivity of many malignant tumors [16,42]. However, we found that there were not reveal any cell cycle disturbance by SH alone, but a significantly decreased iodine-131 induced G2/M arrest and increased S-phase arrest by co-treatment SH and iodine-131, which was same as Zhang et al. found in Hela cells [11]. This special event may due to the elevated phosphorylation level of Chk1 S345, which is important for DNA damage-mediated S-phase checkpoint activation [43].

When DNA damage occurs in cells, such as radiation, elevated levels of p53 always induce a variety of downstream events, including cell cycle arrest, apoptosis and DNA repair or differentiation [44,45]. The results of the present study (Fig. 4) indicated that treatment of PTC cells

---

**Fig. 5.** Activation of apoptosis and other molecules after SH and iodine-131. HTori-3 BCPAP and TPC-1 cells were treated with or with 0.8 mM SH along, RAI along or SH plus RAI 14.8 MBq/ml. (A)The protein expression levels of p53, p21, Fas, Bcl-2, and Bax were determined by western blot analysis, GAPDH was probed as a loading control. The mRNA expression levels of (B) ratio of Bcl-2 to Bax, (C) Fas, (D) p53, and (E) p21 were determined by reverse transcription-quantitative polymerase chain reaction. The data are presented as the mean ± standard deviation of four independent experiments (*P < 0.05). SH, sinomenine hydrochloride; I, iodine-131; ISH, co-treatment of iodine-131 and SH.
with both SH and iodine-131 resulted in significantly increased p53 and p21 expression levels, indicating that the p53 and p21 expression levels are involved in signal transmission in the process of cell apoptosis. Considering the expression of ATM, it can be indicated that DNA damage caused by iodine-131 activates stimulator modification ATM in thyroid cells, then only up-regulate the protein expression of p53 in PTC cells that may cause a transcriptional stimulator modification of p21. Notably the protein expression of p21 in ISH group was lower compared with I-131 group in HTori-3, meanwhile the mRNA expression of p21 was higher which meant the modification and translation of p21 protein in HTori-3 may affect by some other factors, which needs a further study in the future.

Ryan R. et al. demonstrated that BRAFV600E directly promotes radiation resistance through heightened nuclear DNA DSB repair [46]. Our findings join this viewpoint by observing that ATM expression was lower in BCPAP cells compared with TPC-1 cells. Interestingly, both the ratio of Bcl-2 to Bax in BCPAP cells and TPC-1 cells decreased follow by SH treatment added compared with iodine-131 alone. However, Bax protein expression increased, meantime, there was no significant difference in Bcl-2 protein expression in SH and iodine treatment compared with iodine alone in BCPAP cells. The trend of Bax and Bcl-2 protein expression was just on the contrary in TPC-1 cells. These differences may associate with BRAF V600E mutation. It can suggest that BCPAP cells keep a lower radiosensitivity of iodine-131 than TPC-1. BRAF V600E alone is strongly associated with the loss of RAI avidity in recurrent PTC, showing a robust predictive value for failure of RAI treatment of PTC [47–49]. In clinical studies, radioactive iodine(RAI) treatment were more likely be taken in PTC patients follow by BRAF V600E mutation compared with patients with no BRAF V600E mutation [50]. For this situation, the clinic doctors could pay more attention in RAI treatment when facing PTC patients with BRAF V600E mutation.

Overall, the current study demonstrated that synergic radiosensitization of SH and iodine-131 on PTC cells in vitro, which might be supported by the apoptosis, DNA repair and cell cycle checkpoint regulation. Our findings provide evidence that SH appeared to be a novel and promising radiosensitizer for iodine-131 therapy of PTC treatment in clinical. Further investigation of synergic radiosensitization of SH and 131I in vivo is required in order to enable its direct application in clinical nuclear medicine.

Author contributions statement

Aomei Zhao: Conceptualization, Validation, Writing - Original Draft; Jing Zhang: Validation; Yan Liu: Methodolog, Data Curation; Xi Jia: Methodology, Writing- Reviewing and Editing; Xueni Lu: Resources; Qi Wang: Resources; Ting Ji: Resources; Lulu Yang: Resources; Jianjun Xue: Writing- Reviewing and Editing; Rui Gao: Methodology, Writing- Reviewing and Editing; Yan Yu: Data Curation, Formal analysis; Aimin Yang: Conceptualization, Funding acquisition, Writing- Reviewing and Editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors of the present study would like to thank the staff of the
Nuclear Medicine Department of The First Affiliated Hospital of Xi’an Jiaotong University College of Medicine (Xi’an, China) for their support. The project was supported by a grant from the National Natural Science Foundation of China (no. 81871389).

Supplementary materials

Supplementary material associated with this article can be found in the online version, at doi:10.1016/j.tranon.2021.101172.

References

[1] Y. Mao, M. Xing, Recent incidences and differential trends of thyroid cancer in the USA, Endocr. Relat. Cancer 23 (2016) 313–322.
[2] X. Zhu, J. Yao, W. Tian, Microarray technology to investigate genes associated with papillary thyroid carcinoma, Mol. Med. Rep. 11 (2015) 3729–3733.
[3] A. Raposo, S. Morris, M. Oliveira, A. Marques, M. Jone Bento, N. Linsen, Trends in thyroid cancer incidence and mortality in Portugal, Eur. J. Cancer Prevent. 26 (2017) 135–143.
[4] B. Haugen, E. Alexander, K. Bible, G. Doherty, S. Mandel, Y. Nikiforov, F. Pacini, G. Randolph, A. Sawa, M. Schlumberger, K. Schuff, S. Sherman, J. Sosa, D. Stewart, R. Tuttle, L. Wartofsky, 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid carcinoma: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer, Thyroid 26 (2016) 1–133.
[5] GaoHongwei, Bai Peirong, XiaoLin, ShenMengjia, YuQiuxiao, LeiYuanyuan, Huang Wenting, Lin Xiang, Zheng Xinyi, Wei Tao, Yong. Jiang, Ye Feng, Bu Hong, Mediator complex subunit 16 is down-regulated in papillary thyroid cancer, leading to increased transforming growth factor-β signaling and radiosensitivity, J. Biol. Chem. 295 (31) (2020) 10726–10740.
[6] Chen Fukun, Yin Shuting, Feng Zhiping, Liu Chao, Lv Juan, Chen Yuanjiao, Robb Ryan, Yang Linlin, Shen Changxian, Adam R. Wolfe, Webb Amy, Y. Mao, M. Xing, Recent incidences and differential trends of thyroid cancer in the USA, Endocr. Relat. Cancer 23 (2016) 313–322.
[7] A. Pranatharthi, P. Thomas, A. Udayashankar, C. Bhavani, S. Suresh, S. Krishna, J. Thathe, N. Srikantia, C. Rosa, S. Srivastava, RhoC regulates radiosensitivity via cross talk of ROCK2 with the DNA repair machinery in cervical cancer, J. Exp. Clin. Cancer Res. 38 (2019) 392.
[8] Robb Ryan, Yang Linlin, Shen Changxian, Adam R. Wolfe, Webb Amy, Y. Mao, M. Xing, Recent incidences and differential trends of thyroid cancer in the USA, Endocr. Relat. Cancer 23 (2016) 313–322.
[9] Chen Fukun, Yin Shuting, Feng Zhiping, Liu Chao, Lv Juan, Chen Yuanjiao, Chen Hongwei, Bai Peirong, Xiao Lin, Shen Mengjia, Yu Qiuxiao, Lei Yuanyuan, Huang Wenting, Lin Xiang, Zheng Xinyi, Wei Tao, Yong. Jiang, Ye Feng, Bu Hong, Mediator complex subunit 16 is down-regulated in papillary thyroid cancer, leading to increased transforming growth factor-β signaling and radiosensitivity, J. Biol. Chem. 295 (31) (2020) 10726–10740.
[10] A. Zhao et al., A. Zhao, J. Liu, R. Liu, X. Shen, H. Zhu, M. Xing, BRAF the genetic duet of V600E and A1585G: a review of clinical studies, Cancer 82 (2004) 1608–1614.
[11] L. Hernandez Borrero, R. Sikker, A. Lulla, P. Goke, P. Del Valle, X. Tian, S. Zhang, P. Abhosh, W. El-Deiry, p21(WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy, Cancer Res. 76 (2016) 5189–5191.
[12] J. Thatte, N. Srikantia, C. Rosa, S. Srivastava, RhoC regulates radiosensitivity via cross talk of ROCK2 with the DNA repair machinery in cervical cancer, J. Exp. Clin. Cancer Res. 38 (2019) 392.
[13] A. Zhao et al., A. Zhao, J. Liu, R. Liu, X. Shen, H. Zhu, M. Xing, BRAF the genetic duet of V600E and A1585G: a review of clinical studies, Cancer 82 (2004) 1608–1614.
[14] J. Liu, R. Liu, X. Shen, H. Zhu, B. Li, M. Xing, BRAF the genetic duet of V600E and A1585G: a review of clinical studies, Cancer 82 (2004) 1608–1614.
[48] M. Xing, Molecular pathogenesis and mechanisms of thyroid cancer, Nat. Rev. Cancer 13 (2013) 184–199.

[49] M. Xing, B. Haugen, M. Schlumberger, Progress in molecular-based management of differentiated thyroid cancer, Lancet 381 (2013) 1058–1069.

[50] M. Celik, B. Bulbul, S. Ayturk, Y. Durmus, H. Gurkan, N. Can, E. Tastekin, F. Ustun, A. Sezer, S. Guldiken, The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer, Medicinski glasnik 17 (2020) 30–34.